| Methods |
Randomized, double blinded, placebo‐controlled trial |
| Participants |
ALI/ARDS |
| Interventions |
N‐acetylcysteine 40 mg/kg/day for 3 days versus placebo (not stated) |
| Outcomes |
development of ARDS, mortality |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Only states: "patients were randomized". |
| Allocation concealment (selection bias) |
Low risk |
Similar vials for treatment and placebo. |
| Blinding (performance bias and detection bias)
All outcomes |
Low risk |
Patients and investigators were blinded for treatment allocation. |
| Selective reporting (reporting bias) |
Low risk |
|
| Other bias |
Low risk |
|
